Abstract
Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
Keywords: Radiation, heart, animal models, transforming growth factor-beta, renin-angiotensin system, mast cells, endothelin system, sensory nerves, models, transforming, angiotensin, endothelin, sensory, (RIHD), atherosclerosis, pericardial, myocardial fibrosis, pathogenesis, (myocardial necrosis, (PET), (SPECT), (RAS), Endothelial dysfunction, chemokines, TGF-β, mRNA, (Ang II), ACE, Captopril, (Ws), (CGRP), (TNF-α), IGF-1, (MMP), ETA, ETB
Current Drug Targets
Title: Potential Targets for Intervention in Radiation-Induced Heart Disease
Volume: 11 Issue: 11
Author(s): M. Boerma and M. Hauer-Jensen
Affiliation:
Keywords: Radiation, heart, animal models, transforming growth factor-beta, renin-angiotensin system, mast cells, endothelin system, sensory nerves, models, transforming, angiotensin, endothelin, sensory, (RIHD), atherosclerosis, pericardial, myocardial fibrosis, pathogenesis, (myocardial necrosis, (PET), (SPECT), (RAS), Endothelial dysfunction, chemokines, TGF-β, mRNA, (Ang II), ACE, Captopril, (Ws), (CGRP), (TNF-α), IGF-1, (MMP), ETA, ETB
Abstract: Radiotherapy of thoracic and chest wall tumors, if all or part of the heart was included in the radiation field, can lead to radiation-induced heart disease (RIHD), a late and potentially severe side effect. RIHD presents clinically several years after irradiation and manifestations include accelerated atherosclerosis, pericardial and myocardial fibrosis, conduction abnormalities, and injury to cardiac valves. The pathogenesis of RIHD is largely unknown, and a treatment is not available. Hence, ongoing pre-clinical studies aim to elucidate molecular and cellular mechanisms of RIHD. Here, an overview of recent pre-clinical studies is given, and based on the results of these studies, potential targets for intervention in RIHD are discussed.
Export Options
About this article
Cite this article as:
Boerma M. and Hauer-Jensen M., Potential Targets for Intervention in Radiation-Induced Heart Disease, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011405
DOI https://dx.doi.org/10.2174/1389450111009011405 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design The Vectorcardiogram and the Main Dromotropic Disturbances
Current Cardiology Reviews Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Interaction of the Heart and Lungs During Exercise: Physiology and Pathophysiology in Children with Congenital Heart Disease
Current Respiratory Medicine Reviews Hypertensive Left Ventricular Hypertrophy Regression: Does It Matter?
Current Hypertension Reviews Oxidative Stress as a Regulator of Murine Atherosclerosis
Current Drug Targets p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Biological and Pharmacological Effects of Gamma-oryzanol: An Updated Review of the Molecular Mechanisms
Current Pharmaceutical Design Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial (Thematic Issue: Advanced Biomaterial in Clinical Medicine)
Current Medicinal Chemistry Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Potential Use of Dietary Natural Products, Especially Polyphenols, for Improving Type-1 Allergic Symptoms
Current Pharmaceutical Design Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Signal Transduction Therapy of Diabetic Vascular Complication
Current Signal Transduction Therapy